AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results

​AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Best Up and Coming Canadian Stocks to Buy. AbCellera Biologics Inc. (NASDAQ:ABCL) is down more than 23% since its fiscal Q3 2025 business update on November 6. However, Wall Street maintains a bullish sentiment with analysts’ 12-month average price target of $8.5, reflecting 144.96% upside from the current level. ​On November 19, David Martin, PhD, from Bloom Burton reiterated a Buy rating on the stock with a price target of $9. Earlier on November 10, ...